Fig. 5From: Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent MechanismsDose-dependent effects of Oligo AS on HCPT efficacy in LS174T (A) and DLD-1 (B) models. Doses for drugs alone or in combinations are Oligo AS, 1, 10, and 20 mg/kg/day 5 days/week for 2 weeks; and HCPT, 3 mg/kg/day for the first week and 3 mg/kg every other day for remaining treatment period.Back to article page